Inhibikase Therapeutics
Develops IKT-001 as a clinical-stage therapy for pulmonary arterial hypertension.
Something off on this page? Send us feedback.
Profile
Develops kinase-inhibitor therapeutics, with current work centered on IKT-001 for pulmonary arterial hypertension. The business has no approved drugs or product-sales revenue, runs as one reportable segment, and depends on clinical execution, regulatory approval, tolerability, financing, and competition in PAH.
Develops protein kinase inhibitor therapeutics rather than marketed drugs. Current work centers on IKT-001, an oral prodrug of imatinib mesylate for pulmonary arterial hypertension, with IMPROVE-PAH enrolling globally after the company redirected resources toward PAH.
The business is pre-commercial, has no approved products or product-sales revenue, and reports one operating segment. Operations are run from Wilmington, Delaware, with a small full-time employee base and leadership reset under Mark Iwicki after the founder-CEO transition.
Execution depends on enrolling and completing IMPROVE-PAH, securing regulatory approval, showing a tolerability profile that can matter versus imatinib, maintaining financing, and competing with approved and investigational PAH therapies.
Company facts
Key statistics
Year to date +23.8% · Average volume (30d) 614.2K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Jul 31, 2026 | H.C. Wainwright | Reiterate | Buy | $5 | $8 | |
| Jun 10, 2026 | Oppenheimer | Target | $5 | |||
| Dec 11, 2025 | Cantor Fitzgerald | Target | $4 | |||
| Feb 12, 2025 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 11, 2026Q2 FY26 | −$0.11 | −$0.11 | −2.3% | — | — | — | −2.04% |
| May 12, 2026Q1 FY26 | −$0.10 | −$0.10 | 0.0% | — | — | — | −1.04% |
| Mar 26, 2026Q4 FY25 | −$0.12 | −$0.09 | +25.0% | — | — | — | +3.07% |
| Nov 14, 2025Q3 FY25 | −$0.13 | −$0.13 | 0.0% | — | — | — | −0.65% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | |
| Operating income | −$14.6M | −$10.8M | −$12.8M | −$13.8M | −$18.2M | −$21.1M | |
| Net income | −$13.7M | −$9.9M | −$11.9M | −$12.7M | −$16.4M | −$19.6M | |
| Diluted EPS | −$0.15 | −$0.11 | −$0.13 | −$0.14 | −$0.10 | −$0.11 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY21 $3.1M · FY22 $123.4K · FY23 $260.5K · FY24 $0 · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $159.0M · Total debt $0 · Total assets $163.6M · Shareholders' equity $153.3M
Dividends
No dividends on record.
Ownership
Shares outstanding 132.03M · Float —
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Commodore Capital LP | 14.05M | 9.90% | 13G | May 15, 2026 |
| ADAR1 Capital Management, LLC | 13.86M | 9.90% | 13G | May 15, 2026 |
| Sands Capital Ventures, LLC | 13.02M | 9.86% | 13F | May 8, 2026 |
| Perceptive Advisors LLC | 12.64M | 8.90% | 13G | May 15, 2026 |
| Soleus Capital Management, L.P. | 10.88M | 8.24% | 13F | May 14, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Nov 21, 2025 | Sands Capital Life Sciences Pulse Fund II, L.P. | 10 percent owner | +2,068,965 | $1.45 |
Peers
- Merck
Approved PAH disease-remodeling rival with WINREVAIR
- Johnson & Johnson
Established oral PAH franchise across key treatment pathways
- United Therapeutics
Treprostinil PAH leader with inhaled, oral, and infused products
- Liquidia
New inhaled treprostinil entrant with YUTREPIA launch
- Gossamer Bio
Investigational inhaled kinase-pathway PAH competitor
- Insmed
Once-daily inhaled prostanoid challenger advancing TPIP
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Inhibikase Therapeutics | $2.41 | −0.21% | $318.2M | — | — | — | — |
| Merck | $148.19 | −0.08% | $366.18B | 118.7 | 17.2 | 5.5 | +5.1% |
| Johnson & Johnson | $268.40 | +0.13% | $645.95B | 31.1 | 22.4 | 6.6 | +6.6% |
| United Therapeutics | $515.46 | +0.03% | $21.88B | 18.5 | 19.8 | 6.9 | −1.9% |
| Liquidia | $68.25 | +0.87% | $6.02B | 49.4 | 15.4 | 13.3 | +1,842.7% |
| Gossamer Bio | $0.1726 | +2.49% | $83.2M | — | — | 1.6 | −19.6% |
| Insmed | $118.65 | +0.13% | $25.69B | — | — | 22.6 | +296.1% |
| Median | 40.3 | 18.5 | 6.8 | +5.8% |